



RELIEF. REMISSION. FOR REAL.

In clinical trials, ENTYVIO helped many people achieve long-term relief and remission.

Individual results may vary.

#1
**PRESCRIBED
BIOLOGIC**
FOR CROHN'S & UC*

*For Crohn's disease and UC patients combined. Data through September 2023.

Patient portrayal



See the results from ulcerative colitis (UC) clinical studies

GO TO PAGE 2 FOR RESULTS



See the results from Crohn's disease clinical studies

GO TO PAGE 4 FOR RESULTS



ENTYVIO has two ways to administer: IV infusions and self-administered injections under the skin (subcutaneous)

GO TO PAGE 6 FOR ADMINISTRATION INFORMATION



ENTYVIO is gut focused

GO TO PAGE 7 FOR HOW IT WORKS



How do I take ENTYVIO?

GO TO PAGE 8 TO LEARN MORE



What ENTYVIO patients are saying

GO TO PAGE 9 TO HEAR FROM PATIENTS



Get support with *EntyvioConnect*

GO TO PAGE 10 TO LEARN HOW

Ask your healthcare provider about ENTYVIO

What is ENTYVIO?

ENTYVIO is a prescription medicine used in adults for the treatment of:

- moderately to severely active ulcerative colitis (UC)
- moderately to severely active Crohn's disease (CD)

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on page 13.



REAL RESULTS

IN CLINICAL TRIALS FOR MANY PEOPLE WITH MODERATE TO SEVERE ULCERATIVE COLITIS

In two clinical trials, ENTYVIO infused intravenously (IV) delivered results for adults with moderate to severe ulcerative colitis (UC) when other medicines had not worked well enough or could not be tolerated.


The first study evaluated response to ENTYVIO versus placebo at Week 6. The second study included adults who had a previous response to ENTYVIO at Week 6 and evaluated remission at Week 52.



Patient portrayal

Response at 6 weeks


ENTYVIO HELPED NEARLY TWICE as many people achieve response* at 6 weeks vs placebo



*Response is a measure to determine improvement of the patient's UC symptoms and condition.

Remission at 1 year

ENTYVIO HELPED MORE THAN TWICE as many people achieve remission* at 1 year vs placebo



*Remission is a measure to determine when a patient with UC is experiencing a few to no symptoms and an improvement in their condition.

Ask your healthcare provider if ENTYVIO is right for you.

Individual results may vary.

In the ENTYVIO clinical studies, clinical response and remission were defined and measured by improvement in the Mayo Score, an assessment tool that measures stool frequency, rectal bleeding, appearance of the mucosal lining of the colon, and physician assessment.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on page 13.




EVEN MORE REAL RESULTS FROM CLINICAL TRIALS



Patient portrayal

Results with the ENTYVIO Pen


IN A SEPARATE STUDY, THE ENTYVIO PEN HELPED MORE THAN THREE TIMES as many people achieve remission* at 1 year vs placebo



*Remission is a measure to determine when a patient with UC is experiencing a few to no symptoms and an improvement in their condition.

ENTYVIO vs HUMIRA® (ADALIMUMAB)

IN A SEPARATE HEAD-TO-HEAD STUDY, ENTYVIO IV HELPED SIGNIFICANTLY MORE people than HUMIRA® achieve remission at 1 year



*HUMIRA is a registered trademark of AbbVie Inc., North Chicago, IL. For more information related to adalimumab, please see AbbVie.com.

Results your doctor can see



For many people, ENTYVIO helped improve how their intestinal lining looked to their doctor. As early as Week 6, 41% of patients experienced improvement compared to 25% of people on placebo. At 1 year, 52% of patients experienced improvement compared to 20% on placebo.

Ask your healthcare provider if ENTYVIO is right for you.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on page 13.



ENTYVIO MADE REMISSION REAL

FOR MANY PEOPLE WITH MODERATE TO SEVERE CROHN'S DISEASE

In three clinical trials, ENTYVIO delivered results for adult patients with moderate to severe Crohn's disease when other medicines had not worked well enough or could not be tolerated.

The first and second studies evaluated the number of patients who achieved remission on ENTYVIO versus placebo at Week 6; additionally, the second study also evaluated remission at Week 10. The third study enrolled adults who had a previous response to ENTYVIO at Week 6 and evaluated remission at Week 52.



Patient portrayal


Remission at 6 weeks

ENTYVIO HELPED **MORE THAN TWICE** as many people achieve remission* at 6 weeks vs placebo



Remission at 1 year

ENTYVIO HELPED **ALMOST TWICE AS MANY** people achieve remission* at 1 year vs placebo



Ask your healthcare provider if ENTYVIO is right for you.

Individual results may vary.

*Remission is a measure to determine when a patient with Crohn's is experiencing a few to no symptoms and an improvement in their condition.

In the ENTYVIO clinical studies, clinical remission was defined and measured by improvement in the CDAI score, a tool that assesses the number of liquid or very soft stools, abdominal pain, and other measures of disease activity.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on page 13.




EVEN MORE REAL RESULTS FROM CLINICAL TRIALS



Patient portrayal

Remission without steroids


ENTYVIO HELPED TWICE AS MANY people achieve remission without depending on steroids at 1 year vs placebo



Some patients were on steroids at the beginning of the study. ENTYVIO helped some of these patients achieve remission without the use of steroids at Week 52.

Results with the ENTYVIO Pen

IN A SEPARATE STUDY, THE ENTYVIO PEN HELPED MORE PEOPLE achieve remission* at 1 year vs placebo



Ask your healthcare provider if ENTYVIO is right for you.

*Remission is a measure to determine when a patient with Crohn's is experiencing a few to no symptoms and an improvement in their condition.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on page 13.



ONE ENTYVIO. TWO ADMINISTRATION OPTIONS.

You and your healthcare provider can decide how ENTYVIO fits into your lifestyle, with two ways to administer therapy: intravenous (IV) infusions and self-administered injection under the skin (subcutaneous).



ENTYVIO INTRAVENOUS (IV) TREATMENT is administered in an office, infusion center, or at home with medical support.

- A healthcare professional administers ENTYVIO by IV infusion and stays to monitor your treatments
- The ENTYVIO IV is delivered by a needle in the arm and takes about 30 minutes
- After your starting doses, the infusion is given every 8 weeks



THE ENTYVIO Pen offers flexibility in your treatment schedule.

- The ENTYVIO Pen can be administered in several areas of the body
- After your starter IV doses, you or your caregiver inject ENTYVIO under the skin every 2 weeks
- Your healthcare provider will help train you on how to use this single-dose, prefilled pen. You can also receive virtual or in-home injection training before you start
- After you are prescribed the ENTYVIO Pen, a specialty pharmacy will reach out to you regarding coordination and delivery of your prescription



Find an infusion center

Use our infusion center finder to find a location that's convenient for you. Go to infusionfinder.ENTYVIOhcp.com

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.



HOW ENTYVIO TREATS ULCERATIVE COLITIS (UC) AND CROHN'S

What causes UC and Crohn's?


Your immune system uses white blood cells to protect you from infections and other diseases. In people who have UC or Crohn's, the immune system mistakenly identifies certain parts of your gut as invasive material and sends too many white blood cells to the area.

This causes increased inflammation, which can result in permanent damage to your gut.

In UC and Crohn's



Overactive immune system sends **too many** white blood cells into the gut



White blood cells can cause inflammation

How Does ENTYVIO Work?

ENTYVIO works by blocking a type of gut-directed, inflammation-causing white blood cell from entering the gut. This can help control inflammation seen in UC.




What are white blood cells?

White blood cells are part of your immune system. They help your body fight off infections and other diseases.

With ENTYVIO



Overactive immune system sends **too many** white blood cells into the gut



ENTYVIO BLOCKS certain white blood cells from entering the gut, helping to control inflammation

Learn more about the science of ENTYVIO at [ENTYVIO.com/how-entyvio-works](https://www.entyvio.com/how-entyvio-works).

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on page 13.



INTRAVENOUS INFUSION DOSING SCHEDULE

Starting treatment schedule

You will receive ENTYVIO by infusion at **Weeks 0, 2, and 6.**



Week 0



Week 2



Week 6

Maintenance schedule

After your initial doses, you will continue to receive **ENTYVIO by IV every 8 weeks.**



Every 8 Weeks

- In the first year, you'll receive **8 doses of ENTYVIO**
- After the first year, you'll receive **6 doses each year**

SELF-INJECTION DOSING SCHEDULE

Starting treatment schedule

You will receive ENTYVIO by infusion at **Weeks 0 and 2.***



Week 0



Week 2

Go to **page 6** to learn more about infusions and where you can receive yours.

Maintenance schedule

With ENTYVIO self-administration, you will inject ENTYVIO **every 2 weeks** or up to 26 times per year.



Every 2 Weeks

See the full Instructions For Use at [ENTYVIO.com/IFU](https://www.entyvio.com/IFU).

*Your healthcare provider will determine if it's appropriate to transition to self-administration with the ENTYVIO Pen after at least 2 IV doses.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on [page 13](#).



Entyvio Connections

WHAT REAL PATIENTS ARE SAYING

Living with moderate to severe ulcerative colitis (UC) or Crohn's disease can bring its challenges. But for these patients, ENTYVIO has made a difference. Individual results may vary.



“Since starting treating with ENTYVIO, I've noticed a difference in my UC symptoms, and I feel that they are more manageable.”

TARIKA: Living with moderate to severe UC



“After my doctor and I decided that ENTYVIO was right for me, I enrolled in *EntyvioConnect*, which offers insurance support, access to Nurse Educators, helpful resources, and useful tips that helped me manage my condition with my doctor.”

JEN: Patient living with severe Crohn's

REAL PEOPLE. REAL-LIFE EXPERIENCES.

Want to talk to someone who knows the experiences of living with UC or Crohn's firsthand? The Entyvio Connections program can connect you with our Patient Ambassadors for insight and encouragement.

Call [1-833-492-8847](tel:1-833-492-8847) or visit UCCDmentorprogram.com to register for Entyvio Connections.

RON: Living with moderate to severe UC



Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on page 13.



EntyvioCONNECT

WHEN YOU NEED HELP, ENTYVIOCONNECT IS HERE FOR YOU

Living with moderate to severe ulcerative colitis or Crohn's disease can be difficult enough. Managing your treatment shouldn't be. Whether you and your healthcare provider have decided to treat with **IV infusions** or **self-administered injection** under the skin (subcutaneous), the caring team of experts at *EntyvioConnect* is available to guide you with resources designed to make your journey as stress-free as possible.

Once you're prescribed ENTYVIO, you're eligible for *EntyvioConnect*.



One-on-one nurse support

We can pair you with a Nurse Educator who can answer your questions about ENTYVIO resources and help you make the most out of every conversation with a healthcare provider. They cannot, however, provide medical advice.

If you are prescribed self-administered ENTYVIO, virtual and in-person nurse injection training is available through *EntyvioConnect*.



Financial and insurance help

A specialist can help you navigate the insurance and prior authorization process for both IV infusions and self-administered ENTYVIO. They can also help with co-pay assistance and out-of-pocket costs. With our Co-Pay Program, you may pay as little as \$5 per dose.*

*Must meet eligibility requirements.



Ongoing support

Get treatment reminders and useful information, including healthy recipes.



Get connected

Call 1-844-ENTYVIO (**1-844-368-9846**) or sign up at **[ENTYVIO.com/Connect](https://www.entyvio.com/Connect)**.

Safety Considerations with ENTYVIO

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on page 13.



Patient and HCP portrayal

TALKING TO YOUR HEALTHCARE PROVIDER

The questions below can help get your conversation started as you and your healthcare provider explore potential treatment options for your condition. Fill out this page and bring it with you to your next appointment.

How many times have you had to refill your prescription of steroids in the last year?

Never Once Monthly More

How often do you currently take steroids to control flare-ups, as prescribed by your healthcare provider?

Daily Weekly Monthly Once every 2 months Once every 3 months

How many bowel movements do you have a day?

1 2 3 4 5 6 7 8 9 10+

Have you experienced any weight loss?

Yes No

How often do you experience any of the following symptoms?

Abdominal pain or cramping

Never Occasionally Sometimes
Often Always

Diarrhea

Never Occasionally Sometimes
Often Always

Rectal bleeding

Never Occasionally Sometimes
Often Always

Accidents

Never Occasionally Sometimes
Often Always

Constipation

Never Occasionally Sometimes
Often Always

Straining during bowel movements

Never Occasionally Sometimes
Often Always

Lack of energy

Never Occasionally Sometimes
Often Always

Please indicate how you feel using the following scale



Are your current treatments working well enough?

Yes No



Your healthcare provider can help you find a treatment that works best for you.

This is a sample dialogue. It is not, nor is it intended to be, a medical evaluation, examination, advice, consultation, diagnosis, or treatment. Always consult your healthcare professional for all medical and health-related matters.

Please see Important Safety Information on page 13.

QUESTIONS TO ASK YOUR DOCTOR



Here are some examples of questions you may want to ask your doctor as you work together to find the best treatment for your specific needs.

How is a biologic medication different from other medications?

How does ENTYVIO work to help fight inflammation?

How do you and I choose between IV infusion and self-administered injection?

How will I know if the treatment is working for me?

What goals should I set for my treatment?

Could ENTYVIO be right for me?

Please see Important Safety Information on [page 13](#).



Important Safety Information

- **Do not receive ENTYVIO if you** have had an allergic reaction to ENTYVIO or any of its ingredients.
- **ENTYVIO may cause serious side effects, including:**
 - **Infusion-related and serious allergic reactions** can happen while you are receiving ENTYVIO or several hours after treatment. You may need treatment if you have an allergic reaction. Tell your healthcare provider or get immediate medical help if you get any of these symptoms during or after an infusion of ENTYVIO: rash, itching, swelling of your lips, tongue, throat or face, shortness of breath or trouble breathing, wheezing, dizziness, feeling hot, or palpitations (feel like your heart is racing).
 - **Infections.** ENTYVIO may increase your risk of getting a serious infection. Before receiving and during treatment with ENTYVIO, tell your healthcare provider if you think you have an infection or symptoms of an infection, such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, red or painful skin or sores on your body, tiredness, or pain during urination.
 - **Progressive Multifocal Leukoencephalopathy (PML).** People with weakened immune systems can get progressive multifocal leukoencephalopathy (PML) (a rare, serious brain infection caused by a virus). Although unlikely while receiving ENTYVIO, a risk of PML cannot be ruled out. PML can result in death or severe disability. There is no known treatment, prevention, or cure for PML. Tell your healthcare provider right away if you have any of the following symptoms: confusion or problems thinking, loss of balance, change in the way you walk or talk, decreased strength or weakness on one side of the body, blurred vision, or loss of vision.
 - **Liver problems** can happen in people who receive ENTYVIO. Tell your healthcare provider right away if you have any of the following symptoms: tiredness, loss of appetite, pain on the right side of your abdomen, dark urine, or yellowing of the skin and eyes (jaundice).
- **The most common side effects of ENTYVIO include:** common cold, headache, joint pain, nausea, fever, infections of the nose and throat, tiredness, cough, bronchitis, flu, back pain, rash, itching, sinus infection, throat pain, pain in extremities, and with injections under the skin: pain, swelling, itching, hives, bruising, rash, or redness at the injection site. These are not all the possible side effects of ENTYVIO. Call your healthcare provider for medical advice about side effects.
- **Before receiving ENTYVIO, tell your healthcare provider about all of your medical conditions, including if you:** have or think you may have an infection or have infections that keep coming back; have liver problems; have tuberculosis (TB) or have been in close contact with someone with TB; have recently received or are scheduled to receive a vaccine; or if you are pregnant, breastfeeding, plan to become pregnant, or plan to breastfeed.
- **Tell your healthcare provider about all the medicines you take, especially if you take or have recently taken** Tysabri (natalizumab), Tyruko (natalizumab-sztn), a Tumor Necrosis Factor (TNF) blocker medicine, a medicine that weakens your immune system (immunosuppressant), or corticosteroid medicine.

Please see accompanying [full Prescribing Information](#), including the [Medication Guide](#), for ENTYVIO and talk with your healthcare provider.

ENTYVIO is available for:

- **intravenous (IV) infusion: 300 mg vedolizumab.**
- **subcutaneous (SC) injection: 108 mg vedolizumab.**

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call [1-800-FDA-1088](tel:1-800-FDA-1088).

What is ENTYVIO (vedolizumab)?

ENTYVIO is a prescription medicine used in adults for the treatment of:

- moderately to severely active ulcerative colitis (UC).
- moderately to severely active Crohn's disease (CD).

It is not known if ENTYVIO is safe and effective in children under 18 years of age.

©2024 Takeda Pharmaceuticals U.S.A., Inc. 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. ENTYVIO and the ENTYVIO logo are registered trademarks of Millennium Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

US-VED-2960v1.0 04/24